Pfizer

New Delhi: AstraZeneca joins other vaccines that are effective against the Delta variant. COVID-19 Vaccine AstraZeneca offers high levels of protection against the Delta variant (B.1.617.2; formerly the ‘Indian variant), new data…

New Delhi: Pfizer has decided to withdraw the application for emergency use authorisation of its COVID-19 vaccine in India, the pharmaceutical major said on Friday. Incidentally, the US company was the first firm to seek the emergency use…

New Delhi: India will require funding of Rs 80,000 crore for distribution of the COVID vaccine for the next one year, said Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, ZeeNews…

Hyderabad: Pfizer and the Serum Institute of India (SII) had already sought emergency use approval for their COVID-19 vaccines from the Drug Controller General of India (DCGI). Now, Hyderabad-based Bharat Biotech followed suit in urging…

New Delhi: The Serum Institute of India (SII) has sought emergency use authorisation of its vaccine candidate Covishield in the country. The Pune-based SII is conducting the India trials of Covishield vaccine developed by AstraZeneca and…

London: Pharma major Pfizer on Wednesday reported that its COVID-19 vaccine is 95 per cent effective in phase 3 trials and would be applying for emergency US authorization within days. The vaccine, developed with German partner BioNTech…